Patent · US Active

Modified tumor necrosis factor

US7785579B2 · kind B2 · utility

0Cited by
11References
20Claims
0Family size

Assignee

Inventor

Key dates

Filing dateFeb 27, 2006
Grant dateAug 31, 2010
Priority date
Expiry dateJun 5, 2026

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10S930/144
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

Modifying TNF with polyethyleneglycol (PEG) having an approximate weight average molecular weight in the range of about 10,000 to about 40,000, preferably in the range of about 20,000 to 30,000, significantly increases the circulating half-life of the TNF while not increasing its toxicity. As a result, lower doses of the TNF may be administered to effectively treat tumors with fewer, accompanying adverse side effects to the patient.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.